TD Cowen lowered the firm's price target on Myriad Genetics to $6 from $7 and keeps a Hold rating on the shares. The firm said Q1 results were a bit light but the reiterated 2026 guide reflects a steep 2H acceleration, where management was confident that HCT momentum, a refreshed sales force and& new product launches support the outlook.
